SILVERARC CAPITAL MANAGEMENT, LLC Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001816307

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallHealth TiltHigh Turnover how tags are computed

Q2 2025 · 61 positions · Total reported value $483.83M · Top-10 concentration 55.5% · Updated 2026-10-18

Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR

Turnover: 64.6% · 15 new · 20 cut · 18 exited

Active Share (vs S&P 500): 99.8% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -8.8% · vs SPY -10.9% · Prev Value $855.33M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -4.7% · vs SPY -6.9% · Latest Value $784.53M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q2 2025 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC disclosed 61 equity positions with a combined reported value of $483.83M. The filing implies a moderately concentrated portfolio: its ten largest positions account for 55.5% of reported value. HoldingsHub classifies the profile as Small / Health Tilt / High Turnover.

The largest disclosed positions as of Q2 2025 were MRUS ($39.03M), AKRO ($38.09M), VRNA ($33.89M). By sector, the heaviest allocations are Health Care 56.2%, Consumer Discretionary 0.7%. Versus the prior quarter, allocation shifted toward Other (+2.6pp), Consumer Discretionary (+0.7pp) and away from Health Care (-3.3pp).

Versus the prior quarter, SILVERARC CAPITAL MANAGEMENT, LLC opened 15 new positions, trimmed 20 and fully exited 18, a turnover rate of 64.6% of positions. The portfolio's overlap with the prior quarter was 55% of names.

The largest new positions opened in Q2 2025 were CGON ($14.07M), SRRK ($12.08M), PCVX ($9.36M).

Of the 18 positions fully exited versus the prior quarter, the largest were IRON ($11.74M), WVE ($8.49M), TVTX ($7.33M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q2 2025)

  • CGON CG ONCOLOGY INC · $14.07M
  • SRRK SCHOLAR ROCK HLDG CORP · $12.08M
  • PCVX VAXCYTE INC · $9.36M
  • PFE PFIZER INC · $8.35M
  • ABEO ABEONA THERAPEUTICS INC · $5.21M
  • CDTX CIDARA THERAPEUTICS INC · $5.06M
  • MLTX MOONLAKE IMMUNOTHERAPEUTICS · $3.87M
  • CCOI COGENT COMM HOLDINGS INC · $3.59M

Fully Exited (vs previous quarter)

  • IRON DISC MEDICINE INC · prev qtr: $11.74M · history
  • WVE WAVE LIFE SCIENCES INC · prev qtr: $8.49M
  • TVTX TRAVERE THERAPEUTICS INC · prev qtr: $7.33M
  • GILD GILEAD SCIENCES INC · prev qtr: $6.95M
  • TARS TARSUS PHARMACEUTICALS INC · prev qtr: $4.18M
  • ALKS ALKERMES PLC · prev qtr: $4.12M · history
  • OCUL OCULAR THERAPEUTIX INC · prev qtr: $4.04M
  • BBIO BRIDGEBIO PHARMA INC · prev qtr: $3.84M

Insider Transactions (Form 4)

Latest SILVERARC CAPITAL MANAGEMENT, LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

Silverarc Capital Management is an SEC-registered 13F filer based in Boston, MA, United States. As of Q2 2026 it reported 67 US equity positions with a combined value of $855.33M. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).

Firm Snapshot

  • Headquarters: BOSTON, MA, United States
  • SEC registration: 801-116845 (status: Approved), registered 2019-06-21
  • Regulatory AUM (Form ADV): $1.61B as of 2026-03-30
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 3 private funds, of which 2 hedge funds
  • Website: silverarccapital.com

Portfolio Structure

  • 67 positions · $855.33M reported value (Q2 2026)
  • Top 10 holdings = 47.1% of reported value
  • Largest position: ASND (ASCENDIS PHARMA A/S) at 6.4%
  • Average position size: $12.77M

Sector Tilt

  • Health Care 98.1%
  • Financials 1.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q2 2026: 19 new, 16 added, 28 reduced, 20 exited
  • 4 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

Sector Allocation

Health Care 56.2%
Other 43.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 741.97K $39.03M 8.07%
8.07%
Reduce
2 713.81K $38.09M 7.87%
7.87%
Reduce
3 358.30K $33.89M 7.00%
7.00%
Reduce
4 2.02M $27.71M 5.73%
5.73%
Add
5 400.77K $25.32M 5.23%
5.23%
Add
6 249.06K $25.07M 5.18%
5.18%
Reduce
7 1.83M $20.71M 4.28%
4.28%
Add
8 162.97K $20.48M 4.23%
4.23%
Add
9 2.04M $20.00M 4.13%
4.13%
Add
10 1.80M $18.28M 3.78%
3.78%
Reduce
11 204.59K $17.14M 3.54%
3.54%
Add
12 86.55K $14.94M 3.09%
3.09%
Add
13 541.03K $14.07M 2.91%
2.91%
New
14 448.50K $12.12M 2.51%
2.51%
Reduce
15 341.01K $12.08M 2.50%
2.50%
New
16 410.00K $11.64M 2.41%
2.41%
Hold
17 287.80K $9.36M 1.93%
1.93%
New
18 344.34K $8.35M 1.73%
1.73%
New
19 100.20K $7.65M 1.58%
1.58%
Reduce
20 613.39K $6.51M 1.35%
1.35%
Hold
21 5.15M $6.33M 1.31%
1.31%
Reduce
22 207.58K $5.91M 1.22%
1.22%
Add
23 2.76M $5.47M 1.13%
1.13%
Add
24 3.03M $5.40M 1.12%
1.12%
Add
25 2.78M $5.39M 1.11%
1.11%
Hold
26 917.90K $5.21M 1.08%
1.08%
New
27 103.94K $5.06M 1.05%
1.05%
New
28 198.44K $4.04M 0.83%
0.83%
Reduce
29 286.81K $3.88M 0.80%
0.80%
Add
30 82.02K $3.87M 0.80%
0.80%
New
31 175.64K $3.64M 0.75%
0.75%
Reduce
32 500.00K $3.59M 0.74%
0.74%
New
33 2.49M $3.51M 0.72%
0.72%
Add
34 2.57M $3.26M 0.67%
0.67%
Reduce
35 1.25M $3.25M 0.67%
0.67%
Add
36 186.01K $3.23M 0.67%
0.67%
Add
37 253.23K $2.96M 0.61%
0.61%
Add
38 539.59K $2.95M 0.61%
0.61%
Add
39 202.56K $2.82M 0.58%
0.58%
Hold
40 50.00K $2.49M 0.52%
0.52%
New
41 75.96K $2.10M 0.43%
0.43%
Reduce
42 165.39K $1.85M 0.38%
0.38%
New
43 95.81K $1.78M 0.37%
0.37%
Reduce
44 109.26K $1.75M 0.36%
0.36%
New
45 115.28K $1.56M 0.32%
0.32%
Reduce
46 401.54K $1.50M 0.31%
0.31%
Reduce
47 144.70K $1.44M 0.30%
0.30%
New
48 103.03K $1.40M 0.29%
0.29%
Reduce
49 25.00K $1.33M 0.28%
0.28%
Reduce
50 3.13M $926.01K 0.19%
0.19%
Add

FAQ

What did SILVERARC CAPITAL MANAGEMENT, LLC buy in 2025-Q2?

In its 2025-Q2 13F filing, SILVERARC CAPITAL MANAGEMENT, LLC reported 61 equity positions worth $483.83M in aggregate; its largest disclosed positions were MRUS ($39.03M), AKRO ($38.09M), VRNA ($33.89M).

How large is SILVERARC CAPITAL MANAGEMENT, LLC's portfolio?

SILVERARC CAPITAL MANAGEMENT, LLC reported $483.83M of long equity holdings across 61 positions as of 2025-Q2. Top-10 holdings account for 55.5% of reported value.

What is SILVERARC CAPITAL MANAGEMENT, LLC's investment style?

HoldingsHub classifies the portfolio as Small / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/silverarc-capital-management/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →